MedX Health Announces That Dr. Eggert Stockfleth, Director of the University Department of Dermatology at St. Josef-Hospital in Bochum, Germany Has Joined Its Medical Advisory Board

MedX Health Corp. (MedX) (TSX-V: MDX) announced today that Dr. Eggert Stockfleth, Director of the University Department of Dermatology at St. Josef-Hospital in Bochum, Germany has agreed to join MedXs Medical Advisory Board. Dr. Stockfleth was previously the Director of the Skin Cancer Center in Berlin.

The addition of Dr. Stockfleth to our Medical Advisory Board completes our group of highly accomplished physicians from around the world. They are respected thought leaders located in our targeted markets. We are very fortunate to have access to Dr. Stockfleths knowledge and expertise, said Scott Spearn, CEO of MedX.

MedXs non-invasive skin cancer scanning technology is ground-breaking and I am honored to be a member of such an esteemed group of physicians, Dr. Stockfleth said. I see first-hand how MedXs technology is a game-changer in early detection of skin cancers, he added. He noted that his clinic in Bochum receives in excess of 800 calls per day with respect to dermatological issues and has a capacity to handle only about half of the inquiries.

Dr. Stockfleths research on dermatology, oncology and in particular, skin cancer, has been extensively published in peer-reviewed journals. He has contributed to the Journal of Infectious Diseases, International Journal of Cancer, Journal of Investigative Dermatology and The Lancet. He is also the former European President of Skin Care in Organ Transplant Patients Network (SCOPE). In 2008 he was one of the founders of the European Skin Cancer Foundation, which assists in developing and providing standardized treatments on a European level. Dr. Stockfleth graduated from the University of Hamburg and is a Jung-Foundation scholar.

About MedX

MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure„¢ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS„¢, SIMSYS„¢, and MoleMate„¢, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS„¢, SIMSYS„¢, and MoleMate„¢ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This Media Release may contain forward-looking statements, which reflect the Companys current expectations regarding future events. The forward-looking statements involve risks and uncertainties.

MedX Health Corp
Scott Spearn, 905-670-4428 ext 229
and CEO
Media Relations
Deborah Thompson,
[email protected]